



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of

: Klaus Fuchs et al

) Art Unit:

1654

U.S. Appln. No.

: 10/840,037

) Examiner:

T. S. Heard

Confirmation No.: 7763

U.S. Filing Date: May 6, 2004

Title of Invention: Novel Statine Derivatives For The Treatment of Alzheimer's Disease

Attny. Docket No.: 1/1497

Mail Stop Amendment Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

RESPONSE

Sir:

This is in response to a communication from the Examiner, which communication was mailed on May 17, 2005. The communication mailed May 17th comprises a restriction requirement. The Examiner wishes to restrict the claims to either compound claims drawn to a SFT-1 based analog of Formula 1 (claims 1-14) or to a method of treating Alzheimer's disease (claims 15-18).

Applicants, through their attorney, hereby elect claims 1 through 14. As a single species, applicants elect compound number 14 of Table 1, on page 35 of the specification as filed.

Such election is without traverse.

Respectfully submitted,

Mary-Ellen M. Devlin Attorney for Applicant(s)

Reg. No. 27,928

Patent Department Boehringer Ingelheim Corp. 900 Ridgebury Road P.O. Box 368 Ridgefield, CT. 06877 Tel.: (203) 798-4866 June 8, 2005

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to:

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

on June 8, 2005

Mary-Ellen M. Devlin By:

Keg. No. 27,928